Targeting glycan-sensing checkpoints to unleash both innate and adaptive immune response to cancer
Developing novel, first-in-class medicines to transform the treatment of cancer
We are driven to advance a completely new modality for cancer
Palleon Pharmaceuticals Presents Data Suggesting Role of Hypersialylation in Metastatic Melanoma Patients’ Resistance to PD1 Inhibitors
Palleon Pharmaceuticals Appoints Nikola Trbovic to its Board of Directors
View all news
Melanoma patients with multi-Siglec ligands as profiled by HYDRA technology are refractory to PD1 blockade
HYDRA Platform Development to Investigate Siglec-engaging Tumor Immunosuppressive Glyco-codes
View all posters & publications
News
Palleon Pharmaceuticals Presents Data Suggesting Role of Hypersialylation in Metastatic Melanoma Patients’ Resistance to PD1 Inhibitors
February 08, 2021Palleon Pharmaceuticals Appoints Nikola Trbovic to its Board of Directors
Posters & Publications
Melanoma patients with multi-Siglec ligands as profiled by HYDRA technology are refractory to PD1 blockade
HYDRA Platform Development to Investigate Siglec-engaging Tumor Immunosuppressive Glyco-codes